Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

Core Insights - Abpro Corporation and Celltrion, Inc. are set to present new preclinical data for CT-P72/ABP-102, a bispecific antibody targeting HER2 and CD3, at the SITC 2025 Annual Meeting [1][2] Group 1: Presentation Details - The preclinical results will be showcased at SITC 2025, following a prior presentation at the AACR New Drugs on the Horizon Session earlier this year [2] - The CT-P72/ABP-102 poster has been selected as one of the Top 150 abstracts from over 1,300 submissions at SITC 2025 [3] Group 2: Key Findings - CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including those resistant to Enhertu [7] - The dual-affinity engineering of CT-P72/ABP-102 reduces on-target, off-tumor activity, supporting a favorable preclinical safety profile [7] - Strong preclinical activity has been observed in vivo, including efficacy in Enhertu-resistant models [9] Group 3: Safety and Efficacy - A GLP repeated-dose toxicity study in cynomolgus monkeys showed good tolerability at all tested doses, including the highest dose of 80 mg/kg, indicating a favorable safety profile [10] - The molecule has shown robust T-cell activation and PBMC-mediated cytotoxicity in vitro, confirming enhanced tumor selectivity [9] Group 4: Development and Collaboration - Abpro and Celltrion are collaborating to develop CT-P72/ABP-102, which is built on Abpro's DiversImmune platform, aimed at improving selectivity and safety in antibody therapies [11][12] - The companies are working towards assembling a robust IND submission package to initiate the first-in-human trial for CT-P72/ABP-102 next year [5]